Clinical Efficacy of Edaravone on the Patients with Acute Cerebral Infaraction

Objective To evaluate the clinical efficacy of Edaravone on acute cerebral infarction(ACI).Methods Ninty-eight patients who suffered ACI were randomly divided into therapy group(n=49) and control group(n=49).Edaravone was infused at a dose of 30mg,twice a day,meanwhile,Ozagrel and Citicoline were take as basic treatment.The control group was similar to those of therapy group except for Edaravone.Compare with the total efficiency,brain edema scale and necurological functional deficit scores on the 7th,14th day after treatment.Results There was no significant difference between the two group interns of total apparent effect rate(therapy group:91.8%;control group:81.6%).A significant correlation was found between the therapy group and the control group of brain edema(therapy group:81.6%;control group:65.4%).The ratio of necurological functional deficit scores on the 7th,14th day after treatment in therapy group were significantly higher than that in control group.Conclusion Edaravone is a new effective and safe neuroprotective agent for treating acute cerebral infarction,it can accelerate the recovery of neural function after cerebral infarction.There was no distinct adverse reaction in Edaravone group.